首页> 外文OA文献 >Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

【2h】

Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

机译：在伊布勒替尼治疗的慢性淋巴细胞白血病患者进展时添加威尼肽：联合疗法，以防止Ibrutinib Flare

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Paul J. Hampel; Timothy G. Call; Wei Ding; Eli Muchtar; Saad S. Kenderian; Yucai Wang; Jose F. Leis; Thomas E. Witzig; Amber B. Koehler; Amie L. Fonder; Susan M. Schwager; Kari G. Rabe; Daniel L. Van Dyke; Esteban Braggio; Susan L. Slager; Neil E. Kay; Sameer A. Parikh;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare [J] . Hampel Paul J., Call Timothy G., Ding Wei, American Journal of Hematology . 2020,第3期

机译：在伊布勒替尼治疗的慢性淋巴细胞白血病患者进展时添加威尼酮醛：联合疗法，以防止Ibrutinib Flare
2. Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) [J] . Brown Jennifer R., Davids Matthew S., Chang Julie, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在伊布勒替尼 - 幼稚患者的复发/耐火（R / R）慢性淋巴细胞白血病（CLL）后伊布勒替尼氏菌治疗后伊布洛替尼治疗疗法的结果
3. Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib [J] . Jones Jeffrey, Choi Michael Y., Mato Anthony R., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：Venetoclax（VEN）单一疗法治疗依鲁替尼或依达拉西布后复发或难治的慢性淋巴细胞性白血病（CLL）患者
4. 3D Protein-Structure-Oriented Discovery of Clinical Relation Across Chronic Lymphocytic Leukemia Patients [C] . Konstantinos Mochament, Andreas Agathangelidis, Eleftheria Polychronidou, International work-conference on bioinformatics and biomedical engineering . 2017

机译：面向3D蛋白质结构的慢性淋巴细胞白血病患者临床关系的发现
5. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
6. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia [O] . Paul J. Hampel, Timothy G. Call, Kari G. Rabe, 2020

机译：疾病在慢性淋巴细胞白血病患者临时中断急性中断期间
7. A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY) [O] . P. Ghia, L. Scarfò, M. Coscia, 2017

机译：一种MRD引导方法，易于慢性淋巴细胞白血病复发/难治性患者在复发/难治性患者中的组合方法（改进研究）

Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

著录项

相似文献

相关主题

期刊订阅